a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study of the safety and efficacy of ABT-089 in adults with attention deficit-hyperactivity disorder (ADHD).

Trial Profile

a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study of the safety and efficacy of ABT-089 in adults with attention deficit-hyperactivity disorder (ADHD).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2013

At a glance

  • Drugs Pozanicline (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Aug 2011 Extension trial [NCT00443391] states actual End Date is 1 Oct 2008.
    • 18 Aug 2011 Extension trial [NCT00443391] states actual End Date is 1 Oct 2008.
    • 18 Aug 2011 Extension trial [NCT00443391] states actual initiation date is 1 Feb 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top